Baucus Examines Medtronic's GPO Contract Cancellations
This article was originally published in The Gray Sheet
Executive Summary
Sen. Max Baucus is investigating Medtronic's decision earlier this year to cancel several large contracts with hospital group purchasing organizations out of concerns that the firm's actions could increase costs and reduce price transparency in the health care system.
You may also be interested in...
Dropping GPOs: Medtronic's Hawkins Expects More Of It From MedTech
Medtronic CEO Bill Hawkins says he would be "shocked" if some competitors did not follow his firm's lead this year with cancellations of large group purchasing organization contracts.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.